Elsevier published 6 fake journals

Scientific publishing giant Elsevier put out a total of six publications between 2000 and 2005 that were sponsored by unnamed pharmaceutical companies and looked like peer reviewed medical journals, but did not disclose sponsorship, the company has admitted.
Elsevier is conducting an "internal review" of its publishing practices after allegations came to light that the company produced a pharmaceutical company-funded publication in the early 2000s without disclosing that the "journal"

By Bob Grant | May 7, 2009

Scientific publishing giant Elsevier put out a total of six publications between 2000 and 2005 that were sponsored by unnamed pharmaceutical companies and looked like peer reviewed medical journals, but did not disclose sponsorship, the company has admitted.
Elsevier is conducting an "internal review" of its publishing practices after allegations came to light that the company produced a pharmaceutical company-funded publication in the early 2000s without disclosing that the "journal" was corporate sponsored.

The allegations involve the __Australasian Journal of Bone and Joint Medicine__, a publication paid for by pharmaceutical company Merck that amounted to a compendium of reprinted scientific articles and one-source reviews, most of which presented data favorable to Merck's products. __The Scientist__ obtained two 2003 issues of the journal -- which bore the imprint of Elsevier's Excerpta Medica -- neither of which carried a statement obviating Merck's sponsorship of the publication.
An Elsevier spokesperson told __The Scientist__ in an email that a total of six titles in a "series of sponsored article publications" were put out by their Australia office and bore the Excerpta Medica imprint from 2000 to 2005. These titles were: the __Australasian Journal of General Practice__, the __Australasian Journal of Neurology__, the __Australasian Journal of Cardiology__, the __Australasian Journal of Clinical Pharmacy__, the __Australasian Journal of Cardiovascular Medicine__, and the __Australasian Journal of Bone & Joint [Medicine]__. Elsevier declined to provide the names of the sponsors of these titles, according to the company spokesperson.
"It has recently come to my attention that from 2000 to 2005, our Australia office published a series of sponsored article compilation publications, on behalf of pharmaceutical clients, that were made to look like journals and lacked the proper disclosures," said Michael Hansen, CEO of Elsevier's Health Sciences Division, in a linkurl:statement;http://www.elsevier.com/wps/find/authored_newsitem.cws_home/companynews05_01203 issued by the company. "This was an unacceptable practice, and we regret that it took place."
When confronted with the questionable publishing practices surrounding the __Australasian Journal of Bone and Joint Medicine__ last week, Elsevier indicated that it had no plans of looking into the matter further, but that decision has apparently been reversed.
"We are currently conducting an internal review but believe this was an isolated practice from a past period in time," Hansen continued in the Elsevier statement. "It does not reflect the way we operate today. The individuals involved in the project have long since left the company. I have affirmed our business practices as they relate to what defines a journal and the proper use of disclosure language with our employees to ensure this does not happen again."
"I understand this issue has troubled our communities of authors, editors, customers and employees," Hansen added in the statement. "But I can assure all that the integrity of Elsevier's publications and business practices remains intact."
__Correction (May 7): The headline and original version of this story incorrectly indicated that Elsevier had produced seven titles in their "series of sponsored article publications" when in fact the publisher produced only six. __The Scientist__ regrets the error.__
**__Related stories:__***linkurl:Merck published fake journal;http://www.the-scientist.com/blog/display/55671/ [30th April 2009]*linkurl:Elsevier expands biopharma base;http://www.the-scientist.com/blog/display/54420/ [11th March 2008]*linkurl:Merck's fall from grace;http://www.the-scientist.com/article/display/23391/ [May 2006]

Comments

Oh, Elsevier, how could you? Virtually everything else you have done to "add value" to scientific publishing -- like establishing outlandish download charges for every single article -- must certainly come into question now, don't you think?

"But I can assure all that the integrity of Elsevier's publications and business practices remains intact." \n\nIsn't this for us - the consumers of Elsevier's products - to decide?\n\nTo retain their integrity, surely they need to -\n- name and shame the person/s responsible for this scam\n- name the companies involved and the fees involved\n- donate the money that Elsevier was paid for these journal to charity\n- out the authors who knew these were fake journals, and apologise publically to those authors who did not.\n- out the editors who knew these were fake journals, and apologise publically to those editors who did not.\n- identify the articles in Medline that cited papers from these fake journals and include links to information about this scam so that readers can be fully informed.

Did the publishers and editors know they were working for sponsored publications? Journalists at the LA Times were shocked when they found out their paper and Staples Center were sharing revenue. (http://www.pbs.org/newshour/bb/media/july-dec99/la_times_12-16.html).\n\nHere's another question: What scientists have cited research in the journals in laying the groundwork for their published research?

If entire journals can be faked, articles in journals can be faked too. It is the way Big Pharma companies approve, market and advertise their own drugs. We are in a Capitalist System, and money seems more important than integrity, standards of ethics and good taste. \n\nWe need to stop this by asking all the publishers and editors of Journals to raise their standards by checking if the Journal actually exists along with a list of the Editorial Board including a letter with signatures to validate the Journal. In the case of manuscripts, Editors should request to authors to provide along with manuscripts, copies (preferably notarized and in PDF format) of all the original data obtained from the research with signatures from all the authors confirming that the experiments, data and all the content of the manuscripts are genuine and that they have read it and approve its publication. Reviewers should get this copy in order to review the manuscripts before comments are submitted to editors.\n\nI am just wondering how many fake articles with fake data are published out there. The fact that many high quality Journals are recalling published papers with fake data shows that this problem is growing and must be stopped. \n

Since the titles of the fake journals are known, and since there are Australian libraries which hold at least this first one paid for by Merck, it would be most instructive to all concerned scientists and physicians to be able to see pdf files of the other candidates. Believe me, the sponsors will be obvious after a brief look at the documents.\n\nIn medicolegal liability litigation, the detection of any attempt to modify the facts is almost always associated with a total loss of confidence in the honesty of the perpetrators. I realize that a huge pharmaceutical organization like Merck may be too compartmentalized for even such obvious breaches of scientific ethics as the one we now have before us to be readily apparent at the highest administrative levels, but, unfortunately, the presumption of general culpability weighs heavily when such a breach is detected, just as it does, or should do, in tort litigation.

This writer brings up an extremely important point. The typical biosciences article is a distillation of a mass of data subject to interpretation and statistical analysis. The presumption of honesty is an integral part of the referee process. I personally have managed on a couple of rare occasions to secure incontrovertible evidence that the conclusions of a major drug trial submitted to the referee were adjusted to fit the preplanned outcome. Without access to the basic data collected over the usual span three years or more, this kind of fraud cannot be detected, yet it would be a very rare referee who would have or devote the time needed to sift through the basic data. This is presumably the job of the authors! The only solution I can envision is to apply sanctions of such severity when such conduct is detected as to serve as a real deterrent to such behavior. The sometimes impressive fines levied by the federal courts might not be enough because the profits involved can truly be astronomical.

It shook of the scientific world that there are seven fake journals published. Now that we know that there are only six, we can all heave a sigh of relief and join Elsevier and say Halleluja, all is well!The sin was also committed down under and that should add to the relief!\nIt is correct that the response of the scientific community is limited to the factual instance(whch we worship ever so much being scientific and all that) and not bother about an introspective analysis where all it occurs and for what reasons.\nPerhaps we all know that corruption always starts at the top. Where do we pin the primary blame, Merck or Elsevier? That is a sociological query and not a a scientific one.

Let me see...misrepresenting your data in a publication might be called plagiarism or misconduct; but when a publisher decides to misrepresent its product? Isn't that tantamount to fraud?\n\nWe also see El$evier's true colors too! There is a "word" for doing something only for money...\n\nThe entire academic community should call them to the carpet on this!

For me it is lost of time trying to figure out who is the responsible of this fraud. It is just sad to see how "big pharma" has engulfed many scientific journals (editors) and many scientists too, to help in making money by selling extremely expensive drugs of questionable efficacy. Has someone trying to count the number of opinion liders in the biomedicine field who have not received fees (in any form) from the industry.\nAs an oncologist I am frequently astonished by the reporting of phase III trials in "high impact" journals. Many of these trials are strongly biased on their design to show that the "new" product should become the newer standard. This assures for journals high revenues from reprints at least. I am convinced that the ?elseviergate? is just the tip of the iceberg.\n

The sin was also committed down under and that should add to the relief!\nWhy should this be a relief? Given that it was an international company (Merck was German originally, but now mostly USA based, I believe) paying for this and an international company (Elsevier's headquarters are in The Netherlands) publishing these I would say that culpability lies equally in the Northern hemisphere.\nThe companies that did this should be the ones responsible, not the region where it happened.

It's rather amusing to read a calvalcade of comments bemoaning how this ever got past the scientific editorial board, while at the same time totally ignoring content in this article.\n\nThe journal was fake, not the articles. And it was a fake journal not a faked journal.\n\nMerck and Elsevier didn't make anything up. They just selected Merck-friendly articles already out there (which I assume Elsevier already had, or acquired, copyright to), and slapped them together under a brand new title.\n\nThere is no real need to name and shame the authors published in these titles, nor quetsion any research based upon them. Presumeably all the articles had gone through a legitimate peer-review process elsewhere when they were first published.\n\n\nPharmaco-sponsored publications as of themselves aren't automatically an abomination (just a little questionable) - this format can be used to get more information out to doctors.\n\nThe major foul-up appears to be that Merck's involvement wasn't declared, the journal was misrepresented as some kind of independent publication (and moreover, were doctors charged for what is essentially Merck marketing material?).

The root cause of the world economic collapse was a socioethical malaise rooted in greed. Now it appears that this wasn't limited to the financial sector. \n\nIs it any wonder that serious debilitating or fatal diseases that impact huge numbers -- hundreds of millions -- of human beings around the world --e.g., malaria -- remain without truly effective treatments or vaccines, while Viagra, dermal fillers, etc. are making big bucks for their manufacturers and the cost of plain-vanilla medical care in the USA is going through the roof?\n\nPhysicians, heal (heel?) yourselves! \n\n

I think there should be disclosure of the companies involved and they should be put on a Suspect Scientific Pracrices Register. They should also be subject to a review of their practices in the past and should remain on the SSPR; for a specified period, to be scrutinsed on future publications.\n

What about the other "Australasian journal of..." titles? The ones I can find are: \n\n* Australasian journal of asthma\n* Australasian journal of dentistry\n* Australasian journal of depression\n* Australasian journal of gastroenterology\n* Australasian journal of hospital pharmacy\n* Australasian journal of infectious diseases\n* Australasian journal of musculoskeletal medicine\n* Australasian journal of obstetrics & gynaecology\n* Australasian journal of paediatrics\n* Australasian journal of pain management\n* Australasian journal of psychiatry\n* Australasian journal of respiratory medicine\n* Australasian journal of sexual health\n\nLike the admitted-fake Australasian journal of bone & joint medicine, these titles can be found in WorldCat but not in Ulrich's, Pubmed or Elsevier's own Science Direct.\n\nSo what assurance have we that they are not all fake?

Thanks for helping to unravel the truth about the Australian Excerpta series, which appeared fake journals -or really throwaways.\nIt is worrying that a renowned publisher as Elsevier is involved in this.\nBut this affair is less surprising if you know that Excerpta Medica is a MECC, a strategical medical communications agency, partnering with their clients in the pharmaceutical and biotech industries to educate and write papers. ?In the past the pharmaceutical company Wyeth has hired the MECC Excerpta/Medica to produce several scientific papers on the dangers of obesity and on obesity treatment as part of their marketing strategy for Fen-Phen. Mundy documents that Wyeth paid between $15,000 to $20,000 for Excerpta to prepare each article, of which $1,500 would go to the ?named author? as an honorarium.? (cited from a PLOS article)\n\nAlthough both condemnable, I find this ?shaping of articles? in truly peer reviewed journals far more dangerous than the publishing of an evident throwaway. Because it won?t be recognized as such by doctors, who might decide to prescribe medication on basis of wrong or incomplete information. \n\nFor citations and more information see my blogpost here

Elsevier's choice to publish fake journals to support Big Pharma is no different from other publishers' choices to publish biased content in the name of "education": Big Pharma is behind both. I have educational books supposedly authored by doctors and bearing the imprint of our hospital -- when everyone knows that the books were written by paid writers employed by the "sponsoring" Big Pharma company. I think Elsevier's publication of the fake journals is just the tip of the iceberg. The real crime is that not everyone is capable or motivated to judge that this type of publishing is illegitimate. I think that this biased publishing activity is just the next evolutionary step in Big Pharma's unceasing quest to buy alliances with the people who do the legitimate research. Now that direct honoraria are suspect and reportable, Big Pharma pays for "authorship" which is really just a two-way "trick". I'm very glad to see the Elsevier case flagged becasue I think it will raise awareness of this issue in general.

Under the heading of ?personal experience?: One should not lay it at the Australia doorstep alone. Excerpta Medica (US) approached me to ?write a review? on a subject of my expertise. I informed the contact that I would develop the outline, then draft and finalize the paper. The response was essentially, ?no worries?; ?here is an outline, we will write it and you can edit?if you wish?. It became clear that this was no ordinary ?invited review?. The perspective was further validated by an internet search concerning EM. I demurred and refused the "opportunity". \n\nA week later I was informed that someone had agreed to ?play by the rules?. It also became apparent that there was a pharmaceutical underwriter and that this was standard practice. Whether or not they intended to make the combined pieces ?look like a journal? is irrelevant. It was certainly not going to be made clear that this was marketing run amok. \n\nAs an aside, a then post doctoral fellow who I had invited to collaborate periodically notes the value of the lesson learned and the pitfall avoided. And so we accumulate experience. \n\njg\ngrabo040@umn.edu\n\n

In 2006 Peter Gøtzsche, director of the Nordic Cochrane Centre in Copenhagen did a study comparing reviews of drug studies funded by pharmaceutical companies with reviews done without pharma support. He recommends ignoring *ANY* meta-analyses funded by drug companies. \n\nWe do know a lot more about our minds today. We are becoming better and better at finding weaknesses and manipulating minds of publishers, researchers, doctors and consumers of medicine. We need to use that same knowledge to create new systems which would minimise the distortion field affecting the knowledge of medicine today.

The Atrophy Of Objectivity\n\nIf I were to rate the corruptive tactics performed by big pharmaceutical companies during my intimate experience with them , the frequent and intentional strategy of implementing fabricated and unreliable results of clinical trials performed by others possibly tops the list. \n\nA list of corruptive tactics by the pharmaceutical industry that sponsors such trials. By this atrophy of the scientific method absent of authenticity that has been known to occur, harm and damage is possibly done to the health of the public. \n\nMost would agree that the science of research should be sound and as aseptic as possible- completely free of deliberate and reckless interference. \n\nHowever, it appears, money and increased profits can be a catalyst for disregard for human health with the clinical trial process that is largely unregulated. \n\nThis is particularly a factor on post-marketing studies of various pharmaceutical companies, as some pharmaceutical corporations seem to be deliberately conducting nothing less than seeding trials- with about a 50 percent tax credit for these trial sponsors. \n\nTrials that are in fact pointless and void of scientific benefit.\n\nDecades ago, clinical trials were conducted at academic settings that focused on the acquisition of knowledge and the completely objective discoveries of drugs and devices to benefit mankind. \n\nThen, in 1980, the Bayh-Dole Act, Public Law 96-517,was created, which allowed for such places with their researchers to profit off of their discoveries that were performed for pharmaceutical companies and others in the past.\n \nFurthermore, such academic institutions were coerced to license patented inventions to those pharmaceutical companies that will then commercialize these discoveries paid for in large part by the taxpayers who funded this research to a degree.\n\nThis resulted in the creation of for-profit research trial sites without any academic affiliation that are called Contract Research Organizations. \n\nCROS utilize primarily community patient care clinics whose staff are absent of any research training compared with the former researchers that existed decades ago. \n\nBecause of this structure, the clinical trial investigators of these pharmaceutical sponsored trials are likely novice compared with academic researchers. \n\nThis, of course, happens with intent by the sponsor who can and does control all aspects of the clinical trial protocol at the site locations of a clinical trial that the pharmaceutical company structures and even gives the trial the title they want for their marketing purposes. \n\nThese quite numerous CROS are in fact for- profit, with some CROs making billions of dollars a year, and this market continues to grow. \n\nThe trials conducted at such places again are sponsored by pharmaceutical companies that control and manipulate all aspects of the trial being conducted involving their particular drug chosen to be studied. \n\nEtiology for their deception regarding this manipulation is because the pharmaceutical company that sponsors such a trial is basically creating a marketing tool for this drug of theirs to be studied in this manner. \n\nThis coercion is done by various methods of deception in subtle and tacit methods. \n\nAs a result, research in this protocol of the sponsor ensures favorable results of the sponsor?s medication that is involved in the clinical trial they clearly own. \n\nThese activities are again believed to be absent of true or applied regulation to any degree, and therefore have the autonomy to create whatever they want to benefit the pharmaceutical sponsor.\n\nThere likely is a collusive relationship between the sites, the CRO, and the sponsor, as this whole system is planned beforehand by the pharmaceutical sponsor of their clinical trial to again be utilized to increase the market share of the drug studied that they promote. \n\nGuest authorship has been known to be aggressively recruited by sponsors by paying a known opinion leader to sign off on the completed clinical trial. \n\nFurthermore, the pharmaceutical sponsor recruits investigators to be used for this function of what ultimately is a fabricated clinical trial protocol. \n\nThe trial manuscript and protocol design is prepared by those employed by the drug company sponsor upon specific direction of this sponsor on how this should be prepared. \n \nThe medical program coordinator of a particular sponsored trial is an actual employee of the sponsoring drug company. \n\nThis person also may act as the publisher, manuscript version reviewer, and the clinical trial director who works with the drug company?s hired CRO editors whose objectives are to benefit the sponsor. \n\nTypical and ultimate cost of the final manuscript of the trial to the sponsor created by the hired CRO and the recruited ghostwriters exceeds 1000 dollars per page, some have said. \n\nMerck engages in this behavior, which shocked many, as they were always viewed as an ethical pharmaceutical company that always placed patients over profits. \n\nApparently, this is no longer the case. There are other well known and large pharmaceutical corporations that consider this plan of action standard operating procedures to ensure growth of their drugs.\n\nFurther disturbing is that once the creation of the trials is completed, the research paper is often composed with specific directions by the sponsor to writers known again as ghostwriters. \n\nThese people are usually not identified and acknowledged by the sponsor, and may not be trained in clinical research overall, as they are simply freelance writers. \n\nOne does not need research training or certification in order to perform this function. Rarely do clinical trial ghostwriters question their instructions about their assignment, which is clearly deceptive and undocumented by the pharmaceutical sponsor. \n\nAlso, these hired mystery writers are known to make about 100 grand a year performing this deception full time. \n\nThis activity removes accountability and authenticity of the fabricated clinical trial even further. \n\nThe corruptive act is finally completed by the sponsor hiring again a known thought leader as an author to have their name be placed on the trial, while this hired author likely had absolutely no involvement with the trial, or even reviewing the trial is not asked or required by the hired author, others have said. \n\nTo have the trial published, the sponsor has been known to pay an obscure journal, and the sponsor bribes the journal in a few ways, such as the sponsor purchasing from a selected journal thousands of reprints of their study from the journal, for example. \n\nAgain, how often this process is performed is unknown, yet frequent enough to create hundreds of such false writers mentioned earlier and progressively growing research sites to receive the support the pharmaceutical industry. \n\nSo benefits of pharmaceuticals that are studied in such a malicious way potentially can harm patients and their treatment options along with clear safety risks as a result of this process.\n\nThe purchased reprints of the fabricated clinical trial are then bought by the sponsor of the study from the medical journal they hired to publish this trial. \n\nThe reprints are eventually distributed to the sponsor?s sales force to share the content with prescribers, with the sales force completely unaware about this manipulation that has happened with such a trial that benefits the drug they promote for their employer. \n\nAs a bonus, the sponsor may agree to pay the chosen medical journal to advertise their products to be placed in this journal as well.\n\nSuch misconduct discussed so far impedes research and the scientific method with frightening ethical and harmful concerns, as stated previously. \n\nIf so, our health care treatment options with drugs that are claimed to have benefits that are absent have now become unreliable in large part due to such corruptive situations. \n\nNot to mention the absence of objectivity that has been intentionally eliminated with trials produced in this way. \n\nMore now than ever, meds are removed from the market or are given black box warnings due to the damaging effects of drugs approved by the FDA. We as citizens need to dig deep and ask why this is happening.\n\nTransparency and disclosure needs to happen with the pharmaceutical industry for reasons such as this as well as many others, in order to correct what we have historically relied upon for conclusive proof, which is the scientific method. \n\nMore importantly, research should be conducted in a way that the sponsor cannot in any way interfere in such ways described in this article, which would require independent clinical trial sites with no involvement from the maker of the drug studied in a clinical trial.\n\nAnd clearly, regulation has to be enforced not selectively, but in a complete fashion regarding such matters. \nPublic awareness would be a catalyst for this to occur, after initially experiencing a state of total disbelief that such operations actually are conducted by such people, of course. \n\nWe can no longer be dependent on others for our optimal health.\n\nKnowledge is power, and is also possibly a lifesaver.\n \n?Ethics and Science need to shake hands.? ??. Richard Cabot\n\nDan Abshear\n\nAuthor?s note: What has been written was based upon information and belief.\n\nPublished on: www.brainblogger.com\n\n\n

I think this article is closely related to the earlier "Merck published fake journal" (30th April 2009; www.the-scientist.com/templates/trackable/display/blog.jsp?type=blog&o_url=blog/display/55671&id=55671) Therefore, my comments should apply equally to the earlier article also. \nFor all practical purposes, a journal that merely looks like it is a "peer-reviewed" is not different from one that has real peer review, but of a very poor quality. I say this because there are scores of journals published by professional or scientific societies, and in-house journals published by institutions, laboratories, etc., all of which are virtually "captive journals". There is a plethora of such journals in India. They are all nominally peer-reviewed, but the review is often a complete farce. The reviewers may not have expertise in the field of study to which the paper pertains: for instance a person whose [nominal] speciality is nuclear physics, may review a paper on biochemistry. (This also happens routinely in performance assessments for purposes of career advancement: the reviewer would usually be the Head of the laboratory or institution, a titular superior to the person being assessed.) Also, if a conscientious reviewer rejects a paper from a high-profile lab, the journal will black-mark him and send him no more papers to review. At the same time the journal will ensure that the paper gets published somehow or other. Further, in certain fields of study, only a handful of specialists would be available, and they would all be close associates -- and you get the "dog don't eat dog" phenomenon. Besides, most scientists who occupy high positions in India are political appointees, and appallingly ignorant even in basic science (e.g. high school level chemistry): but they are the ones doing most of the "peer review" both for scientific publications and personnel assessment.\n

sciencecommons dot org.\n\nQuote: \n\nThere are petabytes of research data being produced in laboratories around the world, but the best web search tools available can?t help us make sense of it. Why? Because more stands between basic research and meaningful discovery than the problem of search. \n\nMany scientists today work in relative isolation, left to follow blind alleys and duplicate existing research. Data are balkanized ? trapped behind firewalls, locked up by contracts or lost in databases that can?t be accessed or integrated. Materials are hard to get ? universities are overwhelmed with transfer requests that ought to be routine, while grant cycles pass and windows of opportunity close. It?s not uncommon for research sponsors to invest hundreds of millions of dollars in critically important efforts like drug discovery, only to see them fail. \n\nThe consequences in many cases are no less than tragic. The time it takes to go from identifying a gene to developing a drug currently stands at 17 years ? forever, for people suffering from disease.\n\n...\n

As the amount of data that we create in biomedical sciences increases, it becomes increasingly more difficult to establish the validity of any given result. The only solution to this is community engagement. This requires fundamental shifts in the way that we communicate science to each other, but more importantly a fundamental shift in the way we elicit and evaluate response to our work. \n\nWe are building a platform that can be used just for this purpose. Check us out on http://orwik.com or follow our blog on http://orwik.blogspot.com\n\nBarak

"The Scientist obtained two 2003 issues of the journal -- which bore the imprint of Elsevier's Excerpta Medica -- neither of which carried a statement obviating Merck's sponsorship of the publication."\n\n"Obviating" means to make something unnecessary, not, as may have been intended, to make something obvious.

If Elsevier is claiming that this is an isolated incident and that they do not currently operate like they did with the 6 fake journals were published, why do they not tell us who the other 5 journals were funded by?\n\nElsevier is keeping the guilty companies protected so they are still involved and should not claim to be "dirt free" now.\n\nI do not care if there are legal risks, it is no excuse for withholding the information.\n\nThis is blatant hypocrisy.

When I read of these big pharma revellations of misconduct, I reminded me of discussions 1-2 weeks ago in follow up to GSK's restructuring article "Change Broker" in The Scientist. There were some pretty strong criticisms of GSK management in follow comments. Is this becoming a pattern within big pharma?\n\nhttp://www.the-scientist.com/2009/05/1/28/1/\n

I'm surprised that anybody is actually surprised by this at all.\n\nThe corruption of the pharmaceutical industry on the whole, and of course the FDA which is probably second in corruption only to the NCI, the collusion between those 3 and the stooge doctors and researchers(?) they trot out when necessary to lie through their teeth for the requisite coin of the realm, simply breeds such things as fake journals, faked research data, results that keep the negatives hidden or not even mentioned, and suppresses authentic research and results so as to keep the "big 3" as omnipotent...and the people dying and uniformed.\n\nToo bad one can't "Digg" The Scientist though as this sort of information needs a broader audience.\n\nSo I'm not surprised at the fake journals or any faked research...just par for the course and standard operating procedure for the big 3 and their stooges.

In response to the previous comment, you can Digg us -- if you go to the upper right corner of the news story, place your cursor over the "page tools" box, another box will appear with all sorts of options -- Digg, Facebook, Reddit...\n\nThanks!\nAlison McCook\nDeputy Editor

The 7th title was: Australasian journal of musculoskeletal medicine, which was the title of issue 1 of what became: Australasian journal of bone & joint medicine. They surely were attempting to decieve since they obtained an ISSN.

Oh Yes, one can essentially "Digg" but unlike the majority of other important information sites, should a member of Digg want to read the information on The Scientist, they need to register. While it is not overly time-consuming nor overly inconvenient - after all, we all did it - when one is just trying to get at some important information, having to register first is often a sure way to guarantee the "Digger" simply goes back to Digg for a story that doesn't require membership just to read an article.

Today WNYC's "On The Media" top tier radio show credits the Scientist for exposing this story.\n\nhttp://www.onthemedia.org/transcripts/2009/05/29/04\n\nI missed in my skimming of this story on your site that Elsevier had initially refused to acknowledged that this was sponsored content. This was made clearer (to me) in the OTM story.\n\n- Knowlengr